The plasma Tumor Necrosis Factor-α (TNF-α) does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs)

Authors

  • Zahra Samimi Kermanshah University of Medical Sciences, Medical School, Student Research Committee
  • Bahareh Kardideh Kermanshah University of Medical Sciences, Medical School, Student Research Committee
  • Maryam Chalabi Kermanshah University of Medical Sciences, School of Dentistry
  • Parisa Zafari Mazandaran University of Medical Sciences, Faculty of Medicine, Department of Immunology
  • Mahdi Taghadosi Kermanshah University of Medical Sciences, Faculty of Medicine, Department of Immunology https://orcid.org/0000-0002-3516-0130

DOI:

https://doi.org/10.1590/s2175-97902019000418551

Keywords:

Rheumatoid arthritis, TNF-α, DAS-28, DMARD

Abstract

We performed this study to measure the Tumor Necrosis Factor-alpha (TNF-α) plasma level and to survey its correlation with disease activity in the newly diagnosed Rheumatoid Arthritis (RA) patients and those who were under treatment with the combination of Disease-Modifying Anti-Rheumatic Drug (DMARD) plus Prednisolone (PSL).We enrolled 30 newly diagnosed RA patients who received no treatment regarding their disease, 30 patients under treatment with the combination of Methotrexate (MTX) + Hydroxychloroquine (HCQ) + PSL and 30 healthy subjects in this case-control study from September 2017 to December 2017. The level of plasma TNF-α was measured by enzyme-linked immunosorbent assay (ELISA) in each group. For assessment of disease severity, we used Disease Activity Score-28 (DAS-28) formula, and regarding DAS-28, we divided patients into four groups, including remission, low, moderate and high disease activity. There were no significant differences in the plasma level of TNF-α between the newly diagnosed RA patients and subjects who received MTX + HCQ + PSL, as well as healthy controls (p>0.05). There was a significant correlation between plasma levels of TNF-α and DAS-28 in the newly diagnosed patients with RA (r = 0.594, P = 0.001). Targeting TNF-α at the early stage of RA could have more beneficial effects on the amelioration of disease activity.

Downloads

Download data is not yet available.

Downloads

Published

2020-12-09

How to Cite

Samimi, Z. ., Kardideh, B. ., Chalabi, M. ., Zafari, P. ., & Taghadosi, M. . (2020). The plasma Tumor Necrosis Factor-α (TNF-α) does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs). Brazilian Journal of Pharmaceutical Sciences, 56, e18551. https://doi.org/10.1590/s2175-97902019000418551

Issue

Section

Article